Resources

Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

In this blog Richard Turner, the new vice chair of FTAC, examines the UK's overhauled R&D tax regime, which provides competitive incentives and a stable fiscal framework.

WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.

Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.

Ferrer enters into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine

MHRA has granted conditional marketing authorisation for Autolus' treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

European Medicines Agency (EMA) has granted orphan drug designation to PS-002, Purespring’s lead programme, in IgA nephropathy (IgAN).

Sarah Brockbank, Strategy Leader – Complex Medicines at Medicines Discovery Catapult, shares insight into a new regulatory roadmap created by the UK’s Intracellular Drug Delivery Centre (IDDC).

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.

The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.